Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 6/20 | 0.48 |
| ▸ | SIRT1 | Q96EB6 | 6/20 | 0.48 |
| ▸ | SIRT3 | Q9NTG7 | 6/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2915616 | 0.84 | SIRT2 (0.42) | SIRT2SIRT1SIRT3LRRK2PPARA | |
| SCHEMBL2869665 | 0.81 | ALDH1A1 (0.59) | SIRT2SIRT1SIRT3LRRK2TSHR | |
| SCHEMBL2869381 | 0.79 | EPHX2 (0.43) | PPARAKMT2AMEN1NPC1POLB | |
| SCHEMBL2865565 | 0.79 | SIRT2 (0.48) | SIRT2SIRT1SIRT3PPARASMN1; SMN2 | |
| SCHEMBL2865605 | 0.79 | EPHX2 (0.43) | SIRT2SIRT1SIRT3PPARAKMT2A | |
| SCHEMBL2860972 | 0.74 | LMNA (0.40) | PPARAKMT2AMEN1NPC1POLB | |
| SCHEMBL7149299 | 0.72 | NOS1 (0.57) | LRRK2KMT2AMEN1RAB9A | |
| SCHEMBL2871928 | 0.71 | F10 (0.49) | EPHX2 | |
| SCHEMBL3428338 | 0.70 | MAOB (0.52) | SIRT2SIRT1SIRT3PPARAKMT2A | |
| SCHEMBL2915621 | 0.69 | ALDH1A1 (0.52) | SIRT2SIRT1SIRT3LRRK2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1747196-B1 | SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS INC (US) | 2010-02-10 | — | — | EP | claimed |
| US-20090023730-A1 | SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS (US) | 2009-01-22 | — | — | US | claimed |
| EP-1747196-A2 | SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION | Achillion Pharmaceuticals, Inc. (US) | 2007-01-31 | — | — | EP | claimed |
| WO-2006083271-A2 | SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS, INC. (US) | 2006-08-10 | — | — | WO | claimed |
| US-20060025416-A1 | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2006-02-02 | — | — | US | claimed |
| US-7767706-B2 | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2010-08-03 | — | — | US | disclosed |
| EP-1747196-B1 | SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS INC (US) | 2010-02-10 | — | — | EP | disclosed |
| US-20090023730-A1 | SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS (US) | 2009-01-22 | — | — | US | disclosed |
| US-7365068-B2 | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025416-A1 | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | PIGS, NAT1, AADAC | SIRT2 755/4885SIRT1 454/4885SIRT3 432/4885 |
| US-20090023730-A1 | SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION | PIGS, NAT1, AADAC | SIRT2 755/4885SIRT1 454/4885SIRT3 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.